HIV-1 polymorphism: a challenge for vaccine development - a review.
The perspective for the development of anti-HIV/AIDS vaccines became a target sought by several research groups and pharmaceutical companies. However, the complex virus biology in addition to a striking genetic variability and the limited understanding of the immunological correlates of protection have made this an enormous scientific challenge not overcome so far. In this review we presented an updating of HIV-1 subtypes and recombinant viruses circulating in South American countries, focusing mainly on Brazil, as one of the challenges for HIV vaccine development. Moreover, we discussed the importance of stimulating developing countries to participate in the process of vaccine evaluation, not only testing vaccines according to already defined protocols, but also working together with them, in order to take into consideration their local information on virus diversity and host genetic background relevant for the vaccine development and testing, as well as including local virus based reagents to evaluate the immunogenicity of the candidate vaccines.
Morgado
M G
MG
Laboratório de AIDS e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, 21045-900, Brasil. mmorgado@ioc.fiocruz.br
Guimarães
M L
ML
Galvão-Castro
B
B
D016915:AIDS Vaccines / Q000235:genetics*; D015195:Drug Design; D014644:Genetic Variation; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology; D006801:Humans; D011110:Polymorphism, Genetic
D016915:AIDS Vaccines